Illumina Inc. (ILMN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Illumina fell $3.05 (-2.0%) to $147.89 on average volume. Throughout the day, 1,929,468 shares of Illumina exchanged hands as compared to its average daily volume of 2,035,200 shares. The stock ranged in price between $145.35-$155.00 after having opened the day at $151.95 as compared to the previous trading day's close of $150.94. Other companies within the Drugs industry that declined today were: Revance Therapeutics ( RVNC), down 8.4%, Inovio Pharmaceuticals ( INO), down 8.0%, Bacterin International Holdings ( BONE), down 7.6% and CytRx Corporation ( CYTR), down 7.5%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $19.6 billion and is part of the health care sector. Shares are up 36.5% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, 22nd Century Group ( XXII), up 19.7%, Relypsa ( RLYP), up 12.4%, Galectin Therapeutics ( GALT), up 8.8% and Novavax ( NVAX), up 8.5% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement